Table 3 Baseline characteristics of patients with non-metastatic RCC according to PMP score
Parameters | PMP score | ||||
|---|---|---|---|---|---|
0 (n = 7) | 1 (n = 24) | 2 (n = 49) | 3 (n = 84) | P value | |
Gender | 0.728 | ||||
Male (n = 99) | 4 (2.0%) | 17 (10%) | 29 (17%) | 49 (30%) | |
Female (n = 65) | 3 (2.0%) | 7 (4.0%) | 20 (12%) | 35 (21%) | |
Age (years) | 0.051 | ||||
< 65 (n = 119) | 3 (2.0%) | 14 (9.0%) | 35 (21%) | 67 (41%) | |
> 65 (n = 45) | 4 (2.0%) | 10 (6.0%) | 14 (9.0%) | 17 (10%) | |
Smoking | 0.065 | ||||
Yes (n = 51) | 2 (1.0%) | 13 (8.0%) | 12 (7.0%) | 24 (15%) | |
No (n = 113) | 5 (3.0%) | 11 (7.0%) | 37 (23%) | 60 (37%) | |
Drinking | 0.774 | ||||
Yes (n = 23) | 1 (1.0%) | 5 (3.0%) | 6 (4.0%) | 11 (7.0%) | |
No (n = 141) | 6 (4.0%) | 19 (12%) | 43 (26%) | 73 (45%) | |
Hypertension | 0.603 | ||||
Yes (n = 68) | 4 (2.0%) | 11 (7.0%) | 22 (13%) | 31 (19%) | |
No (n = 96) | 3 (2.0%) | 13 (8.0%) | 27 (16%) | 53 (32%) | |
DM | 0.410 | ||||
Yes (n = 16) | 0 (0) | 4 (2.0%) | 3 (2.0%) | 9 (5.0%) | |
No (n = 148) | 7 (4.0%) | 20 (12%) | 46 (28%) | 75 (46%) | |
Anemia | < 0.001 | ||||
Yes (n = 55) | 7 (4.0%) | 14 (9.0%) | 16 (10%) | 18 (11%) | |
No (n = 109) | 0 (0) | 10 (6.0%) | 33 (20%) | 66 (40%) | |
Renal dysfunction | 0.033 | ||||
Yes (n = 8) | 0 (0) | 4 (2.0%) | 2 (1.0%) | 2 (1.0%) | |
No (n = 156) | 7 (4.0%) | 20 (12%) | 47 (29%) | 82 (50%) | |
ALT | 0.387 | ||||
> 13.5 (n = 117) | 3 (2.0%) | 17 (10%) | 35 (21%) | 62 (38%) | |
< 13.5 (n = 47) | 4 (2.0%) | 7 (4.0%) | 14 (9.0%) | 22 (13%) | |
AST | 0.652 | ||||
> 19.5 (n = 68) | 2 (1.0%) | 8 (5.0%) | 20 (12%) | 38 (23%) | |
< 19.5 (n = 96) | 5 (3.0) | 16 (10%) | 29 (18%) | 46 (28%) | |
BUN | 0.171 | ||||
> 7.325 (n = 27) | 2 (1.0%) | 7 (4.0%) | 5 (3.0%) | 13 (8.0%) | |
< 7.325 (n = 137) | 5 (3.0%) | 17 (10%) | 44 (27%) | 71 (43%) | |
PLT | |||||
> 245 (n = 16) | 7 (4.0%) | 3 (2.0%) | 6 (4.0%) | 0 (0) | < 0.001 |
< 245 (n = 148) | 0 (0) | 21 (13%) | 43 (26%) | 84 (51%) | |
MLR | |||||
> 0.31 (n = 57) | 7 (4.0%) | 23 (14%) | 27 (16%) | 0 (0) | < 0.001 |
< 0.31 (n = 107) | 0 (0) | 1 (1.0%) | 22 (13%) | 84 (51%) | |
PNI | |||||
> 47.40 (n = 119) | 0 (0) | 2 (1.0%) | 33 (20%) | 84 (51%) | < 0.001 |
< 47.40 (n = 45) | 7 (4.0%) | 22 (13%) | 16 (10%) | 0 (0) | |
Tumor number | 0.739 | ||||
> = 2 (n = 4) | 0 (0) | 0 (0) | 1 (1.0%) | 3 (2.0%) | |
< 2 (n = 160) | 7 (4.0%) | 24 (15%) | 48 (29%) | 81 (49%) | |
Site | 0.219 | ||||
Left (n = 84) | 2 (1.0%) | 9 (6.0%) | 25 (15%) | 48 (30%) | |
Right (n = 80) | 5 (3.0%) | 15 (9.0%) | 24 (15%) | 36 (22%) | |
Tumor size (cm) | < 0.001 | ||||
> 7.3 (n = 13) | 3 (2.0%) | 4 (2.0%) | 5 (3.0%) | 1 (1.0%) | |
< 7.3 (n = 151) | 4 (2.0%) | 20 (12%) | 44 (27%) | 83 (51%) | |
Grade | < 0.001 | ||||
1 (n = 99) | 3 (2.0%) | 12 (7.0%) | 28 (17%) | 56 (34%) | |
2 (n = 45) | 0 (0) | 7 (4.0%) | 16 (10%) | 22 (13%) | |
3 (n = 7) | 1 (1.0%) | 2 (1.0%) | 2 (1.0%) | 2 (1.0%) | |
4 (n = 6) | 3 (2.0%) | 2 (1.0%) | 1 (1.0%) | 0 (0) | |
T stage | < 0.001 | ||||
1 (n = 134) | 2 (1.0%) | 14 (9.0%) | 41 (25%) | 77 (47%) | |
2 (n = 17) | 3 (2.0%) | 6 (4.0%) | 6 (4.0%) | 2 (1.0%) | |
3 (n = 10) | 1 (1.0%) | 2 (1.0%) | 2 (1.0%) | 5 (3.0%) | |
4 (n = 3) | 1 (1.0%) | 2 (1.0%) | 0 (0) | 0 (0) | |
Tumor hemorrhage | 0.781 | ||||
Yes (n = 12) | 0 (0) | 1 (1.0%) | 4 (2.0%) | 7 (4.0%) | |
No (n = 152) | 7 (4.0%) | 23 (14%) | 45 (27%) | 77 (47%) | |
Tumor necrosis | 0.424 | ||||
Yes (n = 6) | 0 (0) | 0 (0) | 1 (1.0%) | 5 (3.0%) | |
No (n = 158) | 7 (4.0%) | 24 (15%) | 48 (30%) | 79 (48%) | |
Lymphatic and microvascular infiltration | < 0.001 | ||||
Yes (n = 7) | 1 (1.0%) | 4 (2.0%) | 0 (0) | 2 (1.0%) | |
No (n = 157) | 6 (4.0%) | 20 (12%) | 49 (30%) | 82 (50%) | |